Active von Willebrand factor predicts 28-day mortality in patients with systemic inflammatory response syndrome
- 3 April 2014
- journal article
- Published by American Society of Hematology in Blood
- Vol. 123 (14), 2153-2156
- https://doi.org/10.1182/blood-2013-08-508093
Abstract
Endothelial dysfunction contributes to the pathology of systemic inflammatory response syndrome (SIRS). However, endothelial biomarkers are not routinely evaluated in this setting. Here, 275 patients with SIRS and plasma levels of von Willebrand factor (VWF), thrombospondin-1, myeloperoxidase, ADAMTS-13, and active VWF (aVWF) were studied in relation to 28-day mortality. On admission, aVWF levels were higher in nonsurvivors vs survivors (0.69 vs 0.47 µg/mL, P = .019). Patients in the highest tertile of aVWF levels had a lower cumulative survival (86% vs 75%, P = .017) and twofold increased hazard ratio (HR). When adjusted for the Acute Physiology and Chronic Health Evaluation IV (APACHE-IV) score, this difference remained significant (HR 1.82, 95% confidence interval, 1.03-3.3). On admission, no significant differences were measured for the other proteins. These observations suggest that the stimulated release of VWF is not predictive for mortality in patients with SIRS, opposite of the processing of VWF after release. aVWF could be used with the APACHE-IV score to stratify SIRS patients at high mortality risk.This publication has 22 references indexed in Scilit:
- Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis?Biomarkers, 2011
- Inflammation, endothelium, and coagulation in sepsisJournal of Leukocyte Biology, 2007
- Characterization of the interaction between von Willebrand factor and osteoprotegerinJournal of Thrombosis and Haemostasis, 2007
- The presence of active von Willebrand factor under various pathological conditionsCurrent Opinion in Hematology, 2007
- Time course of platelet counts in critically ill patientsCritical Care Medicine, 2002
- Localized reduction of atherosclerosis in von Willebrand factor–deficient miceBlood, 2001
- The epidemiology of the systemic inflammatory responseIntensive Care Medicine, 2000
- von Willebrand FactorArteriosclerosis, Thrombosis, and Vascular Biology, 1998
- Elevated Circulating E-Selectin, Intercellular Adhesion Molecule 1, and von Willebrand Factor in Patients with Severe InfectionAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Increased plasma von Willebrand factor in the systemic inflammatory response syndrome is derived from generalized endothelial cell activationCritical Care Medicine, 1998